换一批
换一批Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
作者：
主题词
抗肿瘤药, 激素(Antineoplastic Agents, Hormonal);乳腺肿瘤(Breast Neoplasms);细胞增殖(Cell Proliferation);化学疗法, 辅助(Chemotherapy, Adjuvant);I类磷脂酰肌醇3-激酶类(Class I Phosphatidylinositol 3-Kinases);临床试验, Ⅱ期(主题)(Clinical Trials, Phase II as Topic);无病生存(Disease-Free Survival);外显子(Exons);女(雌)性(Female);基因表达调控, 肿瘤(Gene Expression Regulation, Neoplastic);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);Ki-67抗原(Ki-67 Antigen);突变(Mutation);肿瘤辅助疗法(Neoadjuvant Therapy);肿瘤分期(Neoplasm Staging);磷酸肌醇3-激酶类(Phosphatidylinositol 3-Kinases);磷酰化(Phosphorylation);比例危险度模型(Proportional Hazards Models);原癌基因蛋白质c-akt(Proto-Oncogene Proteins c-akt);随机对照试验(主题)(Randomized Controlled Trials as Topic);受体, 雌激素(Receptors, Estrogen);受体, 孕酮(Receptors, Progesterone);危险性评估(Risk Assessment);时间因素(Time Factors);治疗结果(Treatment Outcome)
DOI
10.1007/s10549-009-0575-y
PMID
19844788
发布时间
2022-02-24
- 浏览11
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
